头孢曲松钠联合不同浓度痰热清注射液治疗小儿支气管肺炎的疗效及安全性

Ceftriaxone Sodium Combined with Different Concentration of Tanreqing Injection in the Treatment of Children with Bronchial Pneumonia

目的:观察头孢曲松钠联合不同浓度的痰热清注射液治疗小儿支气管肺炎的疗效及安全性。方法:回顾性分析328例头孢曲松联合痰热清注射液治疗的支气管肺炎患儿,按照痰热清药液的稀释倍数分为高(<10倍)、中(10～25倍)、低(>25倍)三个浓度组,设为三个联合治疗组,观察各组临床疗效及安全性。结果:与低浓度组相比,高、中浓度组症状和体征恢复时间较短(P<0.05),临床疗效更优(P<0.05)。中浓度组(3.59%)、低浓度组(2.74%)不良反应发生率比较差异无统计学意义(P>0.05),均低于高浓度联合治疗组(12.50%,P<0.05)。结论:不同浓度的痰热清注射液可对头孢曲松治疗小儿支气管肺炎的疗效与安全性产生影响,按说明书规定的溶液配制浓度适当稀释可安全、有效辅助治疗小儿支气管肺炎,减少药物不良反应。

Objective: To observe the efficacy and safety of ceftriaxone sodium combined with different concentration of Tanreqing injection in the treatment of children with bronchial pneumonia. Methods: Retrospective analysis was used, 328 children with bronchial pneumonia treated with ceftriaxone sodium combined with Tanreqing injection were divided into the high-concentration group (< 10 times), the medium-concentration group (10-25 times) and the low-concentration group (> 25 times) according to the dilution factor of Tanreqing liquid. Efficacy and safety of these groups were observed. Results: Compared with the low-concentration group, the recovery time of symptoms and signs in the high-concentration group and the medium-concentration group was shorter (P<0.05), and the clinical efficacy was better (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the medium-concentration group (3.59%) and the low-concentration group (2.74%)(P>0.05), which was significantly lower than that of the high-concentration group (12.5%, P<0.05). Conclusion: Different concentration of Tanreqing injection can affect the efficacy and safety of ceftriaxone sodium in the treatment of children with bronchial pneumonia. The appropriate dilution of the solution concentration according to the instructions can safely and effectively assist the treatment of bronchial pneumonia in children and reduce the adverse drug reactions.